Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The CardioKinetix Ventricular Partitioning Device (VPD) is intended to isolate the malfunctioning portion of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. By isolating the malfunctioning portion of the left ventricle, it is hypothesized that the left ventricle will pump more effectively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multinational Trial To Evaluate The Parachute Implant System

NCT01286116

Heart Failure Myocardial Infarction

TERMINATED PHASE3

DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR

NCT02073851

Aortic Valve Stenosis

COMPLETED NA

REDUCE LAP-HF III Corvia Protocol 1701

NCT03191656

Heart Failure

RECRUITING

A Multinational Trial to Evaluate the Longterm Safety of the Parachute Implant System

NCT01297296

Heart Failure Myocardial Infarction

TERMINATED

VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial

NCT00483197

End-stage Heart Failure Cardiomyopathies

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VPD Implant System

Percutaneous introduction using standard catheterization techniques of the VPD Implant.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Akinesis or dyskinesis due to myocardial infarction limited to anteroapical region
2. Diagnosis of heart failure for a minimum of 6 months prior to enrollment
3. NYHA Class at time of enrollment, either:

* NYHA Class III or IV - if predominant during the 3-month period prior to enrollment
* NYHA Class II - if diagnosed with NYHA Class III or IV during 3-month period prior to enrollment and ≥ 1 hospitalization for heart failure during 12-month period prior to enrollment
4. LVEF ≤ 40% as measured by echocardiography
5. Left ventricle must have appropriate anatomy as measured by Cardiac CT per the VPD Implant sizing criteria described in the device's Instructions For Use
6. Eligible for cardiac surgery
7. Between 18 and 74 years of age (inclusive)
8. Receiving appropriate medical treatment for heart failure according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult during the three months prior to enrollment
9. Female patients with childbearing potential must have a negative pregnancy test (within 7 days of the procedure) and must agree not to attempt to become pregnant during the course of the study
10. Provide written informed consent
11. Agree to the protocol-required follow-up

Exclusion Criteria

1. Myocardial ischemia requiring PCI or CABG
2. Acute MI (see MI definition) within 60 days of enrollment or patients with suspected evolving MI at time of enrollment
3. Cardiogenic shock within 72 hours of enrollment
4. Revascularization procedure (PCI or CABG) within 60 days of enrollment
5. Patient has received a CRT device within 60 days of enrollment
6. Patient diagnosed with significant valve disease (AI \>1+; MR \>2+) which may or may not require surgery
7. Patient has received an ICD within 60 days of enrollment
8. Patient has received a pacemaker within 60 days of enrollment
9. History of aborted sudden cardiac death, if patient has not received an ICD and has potentially lethal ventricular arrhythmia, VT or VF
10. Patients with a history or a current diagnosis of either persistent or paroxysmal atrial fibrillation as well as patients who present with a contraindication to oral anticoagulant therapy
11. Aortic valve replacement or repair
12. Resting systolic blood pressure is more than 180 mmHg or less than 90 mmHg
13. Resting heart rate more than 120 bpm
14. Cardiac CT or echocardiographic evidence of thrombus in the left ventricle or left atrium
15. History of bleeding diathesis or a major coagulopathy (i.e. platelet count \< 100,000 plts/ml whole blood; PTT or PT \> 1.3 times control value)
16. GI bleed requiring transfusion within the past 3 months
17. Patient has suffered a stroke within the past 6 months
18. Evidence of severe calcification in the VPD Implant attachment zone
19. Evidence of a significant sub-aortic obstruction ("left moderator band") in the area of implant
20. History of Kawasaki's disease
21. Patient has received a heart, lung, liver and/or kidney transplant
22. Patient on dialysis or expected to require hemodialysis within 12 months
23. Patient has chronic liver disease
24. Patient has received intracardiac gene therapy or stem cell therapy
25. Creatinine \> 2.5mg/dl or impaired renal function that places patient at risk of contrast induced renal failure
26. Hypersensitivity to contrast media
27. Allergy or contraindication to clopidogrel or aspirin
28. Evidence of ongoing infection (fever with temperature \> 38°C and/or WBC \> 15,000)
29. Co-morbidities associated with a life expectancy of less than 12-months or there are factors making echo and clinical follow-up difficult (no permanent address, etc.)
30. Patient is currently participating in another investigational device or drug research study for which the follow-up period is not complete

Minimum Eligible Age

18 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No